Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H20ClN5O3 |
Molecular Weight | 377.825 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@H](C[C@]1([H])C[C@H](NC2)C(O)=O)OC3=C(C4=NN=NN4)C(Cl)=CC=C3
InChI
InChIKey=LAKQPSQCICNZII-NOHGZBONSA-N
InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1
Molecular Formula | C17H20ClN5O3 |
Molecular Weight | 377.825 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Dasolampanel (NGX-426) is an orally available competitive antagonist of the AMPA and kainate receptors. The dug originated at Eli Lilly and Horizon Pharma and was developed for the treatment of migraine and neuropathic pain. Dasalompanel was reduced capsaicin-induced pain and hyperalgesia in human volunteers but failed to achieve positive results in phase 2 clinical trials in patients with pain due to osteoarthritis of the knee and diabetic peripheral neuropathic pain.
Originator
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:15:00 GMT 2023
by
admin
on
Fri Dec 15 20:15:00 GMT 2023
|
Record UNII |
1P85D6BE9K
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DASOLAMPANEL
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
51049972
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
XX-76
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
300000037044
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
9436
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
C166510
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
503294-13-1
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
1P85D6BE9K
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
DTXSID401032046
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103869
Created by
admin on Fri Dec 15 20:15:00 GMT 2023 , Edited by admin on Fri Dec 15 20:15:00 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |